Clinical and experimental rheumatology最新文献

{"title":"Impact of a clinical pharmacist consultation on enhancing knowledge and safety skills in patients with chronic inflammatory arthritis treated with bDMARDs.","authors":"Cécile Bottois, Clementina Lopez Medina, Sophie Dumas, Julien Hubert, Sephora Belo, Christian Roux, Ornella Conort, Maxime Dougados","doi":"10.55563/clinexprheumatol/mhtjub","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/mhtjub","url":null,"abstract":"<p><strong>Objectives: </strong>Biologic-disease-modifying anti-rheumatic-drugs (bDMARDs) effectively manage chronic inflammatory arthritis (IA), but carry risks. To address patient knowledge gaps about treatment, pharmacist consultations have been implemented at our hospital. This study evaluated the impact of pharmacist consultations on knowledge and safety skills related to bDMARDs in patients with IA at three (M3), six (M6) and twelve months (M12) post- pharmacist intervention and identified patient factors associated with improved knowledge.</p><p><strong>Methods: </strong>A self-administered questionnaire, BioSecure (score from 0 (worst) to 100 (optimal)), was utilised during consultations to address unlearned bDMARD knowledge with patients. The same questionnaire was administered at M3, M6 and M12. The primary outcome measured patient knowledge by comparing BioSecure mean scores from baseline to others time points. Secondary outcomes included the proportion of patients with good knowledge levels (BioSecure score >84), percentage of patients missing knowledge per topic and the patient factors associated with knowledge improvement at baseline.</p><p><strong>Results: </strong>Among 99 patients, mean (SD) BioSecure score at baseline, M3, M6 and M12 were 70.7 (18.0), 80.9 (15.5), 83.1 (14.5) and 82.5 (14.4) respectively (p<0.001). Percentages of patients with good knowledge at baseline, M3, M6 and M12 were 23.8%, 57.1%, 59.5% and 57.1% respectively (p<0.001). Patient factors associated with improved knowledge included RAPID 3 <7.5, family status, information from community pharmacist, and low Charlson scores.</p><p><strong>Conclusions: </strong>This study highlights the positive impact of pharmacist consultations on enhancing knowledge and safety skills in patients with IA and treated with bDMARDs. The lack of a control group limits interpretation of the finding.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On demand corticosteroid use in the syndrome of undifferentiated recurrent fever: a literature review and results from JIR-CLiPS survey study.","authors":"Ezgi Deniz Batu, Seher Sener, Mariana Rodrigues, Caroline Vinit, François Hofer, Katerina Laskari, Ricardo Craveiro Costa, Margarida Santos Faria, Gulcan Ozomay Baykal, Oksana Boyarchuk, Olivier Gilliaux, Konstantinos Pateras, Hafize Emine Sonmez, Natasa Toplak, Marco Gattorno, Michaël Hofer","doi":"10.55563/clinexprheumatol/jmtag4","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/jmtag4","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to analyse the strategies of physicians regarding corticosteroid use in syndrome of undifferentiated recurrent fever (SURF) and examine the published data on this topic.</p><p><strong>Methods: </strong>The JIR-CliPS questionnaire which addresses physicians' practices about on demand corticosteroid use in SURF was distributed via e-mail to potential respondents. We systematically reviewed the MEDLINE and Scopus databases and extracted the data about on demand corticosteroid use in SURF.</p><p><strong>Results: </strong>One hundred thirty-seven physicians (F/M=2.5; 66.4% paediatric rheumatologists) from 45 countries responded to the survey. Around 70% of physicians prescribe corticosteroids for SURF flares. Most physicians (81.9%) do not use corticosteroids in SURF patients routinely, and this practice is more common among less experienced physicians (p<0.001). Prednisolone at a dose of 1 mg/kg (54.4%) was the most commonly preferred corticosteroid. The most common definition of response to corticosteroids was \"response within 12 hours\" (51.6%). Most respondents (59.5%) consider changing treatment if corticosteroids cause a decrease in quality of life. We found 10 articles in the literature describing 239 SURF patients treated with on demand corticosteroids. The most frequently preferred corticosteroid was prednisolone (63.8%). The response to corticosteroids was 70.8% and an increase in attack frequency was observed in almost 40% of patients.</p><p><strong>Conclusions: </strong>On demand corticosteroid use is not uncommon in the acute management of SURF attacks. However, most physicians do not use corticosteroids routinely and there is no consensus regarding the definition of response to treatment and when to change treatment neither in our survey results nor in the literature.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydroxychloroquine inhibits the PI3K/AKT pathway in synovial fibroblasts of rheumatoid arthritis and alleviates collagen-induced arthritis in mice.","authors":"Xiaocheng Wang, Jiaxin He, Jianqiu Zhong, Juan He, Deli Wang, Lu Bai, Hongxi Shang, Qingwen Wang","doi":"10.55563/clinexprheumatol/tczujg","DOIUrl":"10.55563/clinexprheumatol/tczujg","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effects of hydroxychloroquine (HCQ) in rheumatoid arthritis (RA), particularly on fibroblast-like synoviocytes (FLS).</p><p><strong>Methods: </strong>We analysed the R (-) and S (+) enantiomers of HCQ. Cell viability and proliferation inhibition were quantified using CCK-8 and 5-ethynyl-2'-deoxyuridine (EdU) assays, respectively. Flow cytometry was employed to analyse cell cycle arrest and apoptosis induction. Transwell assays were conducted to evaluate cellular motility. Molecular docking simulations with key targets predicted binding interactions. The therapeutic efficacy was validated in a collagen-induced arthritis (CIA) mouse model.</p><p><strong>Results: </strong>The study finds that these enantiomers in a racemic combination, known as Rac-HCQ, are potent in arresting the growth of RA-FLS by inhibiting cell migration and invasion through downregulation of vimentin expression, inducing apoptosis via increased bax expression, and promoting cell cycle arrest by suppressing CDK1, cyclins A2, and B1. In vivo experiments showed that Rac-HCQ significantly reduced symptom severity in collagen-induced arthritis (CIA) mice. RNA sequencing suggests that Rac-HCQ alters the disease pathway in RA-FLS by blocking the PI3K/AKT pathway.</p><p><strong>Conclusions: </strong>Our molecular docking studies indicate KIT, SRC, and PIK3A may potentially serve as the targets of Rac-HCQ in RA. These findings reveal the potential of Rac-HCQ to modulate the functions of RA-FLS and mitigate CIA manifestations, principally through its interaction with the pathway PI3K/AKT.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"829-840"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cluster analysis identifies the differential impact of disease activity and severity on functional status and patient satisfaction in rheumatoid arthritis: the FRANK registry.","authors":"Yukio Akasaki, Hisakata Yamada, Masakazu Kondo, Jun-Ichi Fukushi, Koji Sakuraba, Tomoya Miyamura, Motoko Ishida, Masataka Nakamura, Yasushi Inoue, Tomomi Tsuru, Toshihide Shuto, Seiji Yoshizawa, Masanobu Ohishi, Kenta Kamo, Akihisa Haraguchi, Akira Maeyama, Yojiro Arinobu, Hiroki Mitoma, Masahiro Ayano, Nobuyuki Ono, Toshifumi Fujiwara, Daisuke Hara, Ryosuke Yamaguchi, Ryosuke Tsurui, Keitaro Yasumoto, Takahiro Natori, Toshiaki Sugita, Hiroaki Niiro, Yasuharu Nakashima","doi":"10.55563/clinexprheumatol/7emd6z","DOIUrl":"10.55563/clinexprheumatol/7emd6z","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of the present study was to investigate the differential impact of disease activity and severity on functional status and patient satisfaction in rheumatoid arthritis (RA) using cluster analysis on data from the FRANK registry.</p><p><strong>Methods: </strong>Data from 3,619 RA patients in the FRANK registry were analysed. Patients were grouped using hierarchical and k-means cluster analyses based on age, physician's global assessment (PhGA), patient's pain assessment (PtPA), and Steinbrocker stage. Clusters were evaluated for differences in functional status (mHAQ), quality of life (EQ5D), and patient satisfaction.</p><p><strong>Results: </strong>Five distinct patient clusters were identified. In hierarchical cluster analysis, Cluster 1 (n=1195, 33.0%) and 2 (n=641, 17.7%) with lower disease activity and severity demonstrated better functional outcomes (mHAQ: 0.18±0.30 and 0.15±0.26, respectively) and higher satisfaction, with treatment efficacy scores of 1.9±0.7 and 2.0±0.7, respectively (1: very satisfied to 6: very unsatisfied). Cluster 3 (n=1117, 30.9%), characterised by less activity and more severity, showed significant joint damage (Steinbrocker stage III-IV: 95.4%) despite controlled inflammation. Cluster 4 (n=385, 10.6%), characterised by patient-physician discordance in disease activity (mean PhGA: 0.9±0.5; mean PtPA: 5.0±2.1), had a more pronounced negative effect on satisfaction. Cluster 5 (n=281, 7.8%), with more activity and moderate severity, had the poorest outcomes in functional status (mHAQ: 0.87±0.65), quality of life (EQ5D: 0.60±0.17), and satisfaction, with a treatment efficacy score of 2.9±0.9. k-Means clustering produced overall similar clusters to hierarchical clustering, allowing the same labels for Cluster 1 to Cluster 5.</p><p><strong>Conclusions: </strong>The study highlights the importance of understanding the heterogeneous nature of RA and its impact on patient outcomes. Personalised treatment approaches that address both objective disease measures and subjective patient experiences are essential for optimising RA management. Identification of distinct patient phenotypes, particularly those in Clusters 3, 4, and 5, may guide tailored interventions to improve treatment satisfaction and long-term outcomes in RA.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"861-866"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: a retrospective longitudinal monocentric pilot study.","authors":"Elvis Hysa, Andrea Casabella, Nicola Iandolino, Emanuele Gotelli, Carlo Genova, Enrica Teresa Tanda, Carmen Pizzorni, Vanessa Smith, Alberto Sulli, Maurizio Cutolo, Sabrina Paolino","doi":"10.55563/clinexprheumatol/e49am5","DOIUrl":"10.55563/clinexprheumatol/e49am5","url":null,"abstract":"<p><strong>Objectives: </strong>Immune-mediated adverse events (irAEs) from immune checkpoint inhibitors (ICIs) often require high-dose glucocorticoids (GCs), which can promote cancer progression and counteract ICI benefits. This study evaluated the articular and oncologic clinical outcomes of ICI-induced arthritis treated with methotrexate (MTX) as a GC-sparing agent.</p><p><strong>Methods: </strong>Adult patients with ICI-induced arthritis in 2023 were included. Arthritis was assessed using the disease activity score on 28 joints by C-reactive protein (DAS28-CRP), with follow-ups every 3 months. All patients received subcutaneous MTX, and oncologic outcomes were evaluated using RECIST 1.1 criteria after one year.</p><p><strong>Results: </strong>Fourteen patients (median age 74.5 years) with melanoma (64.3%), colorectal cancer (14.3%), lung cancer (14.3%), or Hodgkin's lymphoma (7.1%) were treated with PD1 antagonists (92.9%) or combined with CTLA4 blockers (7.1%). Arthritis presentations included oligo-arthritis (36%), mono-arthritis (29%), polyarthritis (21%), and polymyalgia rheumatica-like syndrome (14.3%), with a mean onset of 4.7±3.7 months post-ICI. MTX was started for all at a mean dose of 9.5±1.5 mg weekly, beginning at the first rheumatology visit in 78.5% of patients. Over a mean follow-up of 12.8±4.6 months, DAS28-CRP scores improved significantly, and prednisone dosage was in all reduced (3.6 mg at V4 vs. 8.4 mg at V0, p=0.003). No major MTX-related toxicities were noted. Cancer responses at follow-up were complete (50%), partial (21.4%), stable disease (7.1%), and progression (21.5%).</p><p><strong>Conclusions: </strong>The use of MTX in ICI-induced arthritis showed promising results in reducing GC dosages and managing the inflammatory articular activity, with no major toxicities observed over one year. These findings suggest that MTX may be a viable GC-sparing option in this context, but larger, controlled studies are needed to confirm these observations and better understand the impact on both articular and oncologic outcomes.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"867-873"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence software in biomedical imaging: a pharmaceutical perspective on radiology and contrast-enhanced ultrasound applications.","authors":"Giovanni Valbusa, Alberto Fringuello Mingo, Sonia Colombo Serra","doi":"10.55563/clinexprheumatol/dknvfz","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/dknvfz","url":null,"abstract":"<p><p>Artificial intelligence (AI) is rapidly transforming radiology, with over 200 CE-marked products in the EU and more than 750 AI-based devices authorised by the FDA in the US, mainly used for x-ray, CT, MRI, and ultrasound imaging. Despite regulatory challenges, the adoption of AI in radiology is growing, driven by venture capital funding and anticipated cost and efficiency benefits. Clinical and economic barriers, inconsistent performance, integration challenges, and lack of reimbursement are currently hindering the widespread adoption of AI. However, the role of AI in the future of medical imaging is generally expected to be significant. Contrast agents are crucial in imaging for improving sensitivity and specificity, widely used in angiography, cardiology, and oncology. AI can optimise the use of these agents, reducing dosages and improving image quality.Moreover, AI's synergy with contrast agents in enhancing image clarity and supporting diagnostic accuracy holds significant potential for advancing clinical practices. In summary, the integration of AI with contrast media in radiology offers promising improvements in image quality, diagnostic accuracy, and operational efficiency, although clinical and regulatory hurdles must be addressed for broader application.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":"43 5","pages":"822-828"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage requirements for abatacept response in rheumatoid arthritis.","authors":"Baptiste de Maleprade, Baptiste Gérard, Pauline Brevet, Gaëtan Riou, Sophie Candon, Olivier Boyer, Olivier Vittecoq, Thierry Lequerré, Manuel Fréret","doi":"10.55563/clinexprheumatol/s42d3g","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/s42d3g","url":null,"abstract":"<p><strong>Objectives: </strong>Abatacept (ABA) is used for its ability to dampen T cell co-stimulation and because it could act on antigen-presenting cells in an indoleamine 2,3-dioxygenase (IDO)-dependent manner. The objective of this study was to identify biomarkers of ABA response in rheumatoid arthritis (RA) patients and to determine the involvement of IDO.</p><p><strong>Methods: </strong>RA patients' samples were collected before and after ABA treatment. Clinical response was assessed after 6 months, macrophage phenotype was assessed by flow cytometry. IDO transcript expression were quantified in blood cells by RT-qPCR. In vitro assay: GM-CSF or M-CSF monocyte-derived macrophages from healthy donors were polarised with LPS, with or without IFN-g, and co-cultured with T cells in the presence of anti-CD3, with or without ABA. Macrophage phenotype and T cell proliferation were assessed.</p><p><strong>Results: </strong>In RA patients, the frequency of CD16- CD64+ CD86high macrophages pre-treatment was increase in ABA good responders compared to non-responders. ABA seemed to increase IDO production. In vitro, ABA reduced the proliferation of T cells activated by anti-CD3 and macrophages differentiated and polarised with GM-CSF+LPS+IFN-γ. This inhibitory effect of ABA was abolished by blockade of IDO.</p><p><strong>Conclusions: </strong>ABA response in RA patients is associated with a particular pro-inflammatory macrophage phenotype pre-treatment and IDO is required for ABA effect. These findings reveal predictive markers of ABA response and the involvement of the IDO pathway.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":"43 5","pages":"874-879"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STEp-down approach in MEthotrexate use for the Treatment of Rheumatoid Arthritis (STEMETRA): a pilot study demonstrating efficacy and safety of short-term, high dose methotrexate.","authors":"Monica Pendolino, Teodora Serban, Giorgia Ferrari, Paola Diana, Antonia Locaputo, Dario Camellino, Andrea Giusti, Gerolamo Bianchi","doi":"10.55563/clinexprheumatol/kv54k5","DOIUrl":"10.55563/clinexprheumatol/kv54k5","url":null,"abstract":"<p><strong>Objectives: </strong>Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment, showing a suitable efficacy-safety profile, relatively low-cost, and versatile dosages and routes of administration. However, there are no clear indications yet on the optimal use of MTX in RA, whereas existing recommendations disagree on relevant aspects. STEMETRA is a 16-week open-label, monocentric, pilot study aimed at evaluating the efficacy and the safety of a step-down strategy of using subcutaneous (sc) MTX in patients with RA.</p><p><strong>Methods: </strong>The study consists of the administration of a starting dose of MTX 50 mg sc/week for 4 weeks, to be subsequently reduced to 15 mg/week in a 12-week period. Fifteen RA patients naive to any disease specific therapy were enrolled.</p><p><strong>Results: </strong>One patient was lost to follow-up after week 12, 4 patients withdrew because of adverse events, therefore, 10 patients concluded the study. Mean DAS28(CRP) at baseline was 5.6 (±0.37 SE), whereas, at week 16, mean DAS28(CRP) was 1.6 (±0.41SE). Most patients who concluded the study achieved ACR70 response and remission (7 out of 10), whereas three still showed moderate disease activity.</p><p><strong>Conclusions: </strong>In this study, the step-down MTX approach was effective in inducing remission in most of the patients enrolled, without increasing the risk of adverse events. Thus, short-term higher dosages of MTX could be more effective in reaching remission earlier. Nonetheless, these results should be confirmed in larger populations of patients.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"841-846"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.","authors":"Yusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, Jonathan Britt, Sarah Kennedy, Mark S Fineman, Ismail Simsek, Emily Solomon, Timothy E McAlindon","doi":"10.55563/clinexprheumatol/hjt118","DOIUrl":"10.55563/clinexprheumatol/hjt118","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the efficacy, safety, and tolerability of intraarticular (IA) lorecivivint (LOR) in the treatment of knee osteoarthritis (OA).</p><p><strong>Methods: </strong>Patients with American College of Rheumatology criteria-defined knee OA, Kellgren-Lawrence (KL) grades 2-3, and medial Joint Space Width (JSW) by radiograph between 1.5 and 4 mm in the target knee were enrolled in this phase 3, 56-week, multicentre, double-blind, placebo-controlled study. Patients were randomised (1:1) to receive a single IA injection of 0.07 mg LOR or vehicle placebo (PBO) on Day 1. The primary endpoint was the change from baseline in pain Numeric Rating Scale (NRS) at Week 12. Additional outcomes included the change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function, WOMAC Pain, Patient Global Assessment, medial JSW, and safety.</p><p><strong>Results: </strong>513 patients were randomised. Baseline mean medial JSW was 2.61 (±0.7) mm. The mean change from baseline in weekly average of daily Pain NRS at Week 12 was LOR -2.24 (± 0.13) compared with PBO -2.49 (± 0.13); p=0.185, 95% confidence interval (CI) (-0.12, 0.62). No discernable treatment effects of LOR compared with PBO were revealed by the analysis of other endpoints. Neither treatment group showed meaningful medial JSW loss over 52 weeks. Incidences, severity, and relationship to study treatment of AEs were similar between LOR and PBO treatment groups.</p><p><strong>Conclusioins: </strong>In this study, LOR was well tolerated although it did not meet the primary endpoint of change from baseline in target knee Pain NRS at Week 12.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"854-860"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gout: one year in review 2025.","authors":"Leonardo Punzi, Laura Scagnellato, Paola Galozzi, Chiara Baggio, Amelia Damasco, Francesca Oliviero, Roberta Ramonda","doi":"10.55563/clinexprheumatol/9sdln5","DOIUrl":"10.55563/clinexprheumatol/9sdln5","url":null,"abstract":"<p><p>The incidence of gout has increased steadily over the last decades and its management is still unsatisfactory. Growing evidence highlights the multifactorial etiology of this disease encompassing genetic predisposition, environmental stimuli and gut dysbiosis. Recent advances in biomolecular and computer sciences allowed to gain more and more genetic, epigenetic, transcriptomic, proteomics and metabolomics insights into hyperuricaemia and gout-related molecular mechanisms. Moreover, the interplay between gout and cardiovascular, metabolic and renal diseases may potentially offer novel targets for anti-inflammatory and urate-lowering therapies.This annual review aims to provide the latest updates on gout research, epidemiology, genetics, molecular mechanisms, diagnostic approach, and therapeutic advances.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"799-808"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}